Summary
Three patients with renal insufficiency requiring hemodialysis were treated with carboplatin at 100 mg/m2 in combination with etoposide for advanced germ-cell tumor (GCT, two cases) or Adriamycin + vinblastine for a transitional-cell carcinoma of the ureter (one case). Hemodialysis was performed 24 h after the administration of carboplatin. Both patients with GCT achieved a complete response, and the patient with transitional-cell carcinoma of the ureter was inevaluable for response but his disease has not progressed. The dose of carboplatin was increased in one patient as renal function improved on therapy. In two patients, the pharmacokinetics of carboplatin were determined; the pre-dialysis half-lives, AUC, and total body clearances of free carboplatin-derived platinum were estimated to be 32 and 18.3 h, 4.93 and 6.17 mg ml−1 min, and 18.2 and 18.7 ml/min, respectively. The dialysis elimination half-lives (t1/2β) of 2 and 3 h, respectively, for these two patients were markedly lower than the predialysis values, indicating that carboplatin was dialyzed. In summary, carboplatin can be given to patients with severe renal insufficiency. Adequate AUCs were achieved and dialysis limited systemic exposure to free carboplatin.
Similar content being viewed by others
References
Ahmed T, Bosl GJ, Hajdu S (1985) Teratoma with malignant transformation in men. Cancer 56: 860–863
Akaza H, Hagiwara M, Deguchi N, Kawai T, Satomi Y, Matsuda T, Miki T, Ueda T, Kotake T, Tazaki H, Aso Y, Niijima T, for the Carboplatin Study Group (1989) Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract. Cancer Chemother Pharmacol 23: 181–185
Bosl GJ, Gluckman R, Geller N, Golbey RB, Whitmore WF, Herr H, Sogani P, Morse M, Martini N, Bains M, McCormack P (1986) VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors. J Clin Oncol 4: 1493–1499
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies withcis-diammine-1,1-cyclobutanedicarboxylate platinum(II). Cancer Chemother Pharmacol 9: 140–147
Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748–1756
Curt GA, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE, Collins JM (1983) A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241 240). Cancer Res 43: 4470–4473
Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing scheme for thecis-diamminedichloroplatinum analogue diamminecyclobutanedicarboxylatoplatinum Cancer Res 45: 6502–6506
Einhorn L (1981) Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41: 3275–3280
Farhangi M, Weinstein SH (1987) Carboplatin, etoposide, and bleomycin for treatment of stage IIC seminoma complicated by acute renal failure. Cancer Treat Rep 71: 1123–1124
Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York
Gibson TP, Reich SD, Krumlovsky FA, Ivonavich P, Gonczy C (1978) Hemoperfusion for methotrexate removal. Clin Pharmacol Ther 23: 351–355
Goutette A, Lemoine R, Adhemar J, Kleinknecht D, Man N, Droz J, Macquet J (1981) Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. Cancer Treat Rep 65: 665–668
Harland S, Horwich A (1987) What dose of carboplatin can be combined with etoposide and bleomycin in patients with testicular cancer (abstract 184)? Proc Am Soc Clin Oncol 6: 48
Harland SJ, Newell DR, Siddik Z, Chadwick R, Calvert AH, Harrap KR (1984) Pharmacokinetics ofcis-diammine-1,1-cyclobutanedicarboxylate platinum in patients with normal and impaired renal function. Cancer Res 44: 1693–1697
Horwich A, Dearnaley DP, Duchesne GM, Williams M, Brada M, Peckham MJ (1989) Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol 7: 1150–1156
Horwich A, Dearnaley D, Harland S, Peckham MJ, Hendry WF (1989) Carboplatin-etoposide-bleomycin (CEB) combination chemotherapy is effective in good prognosis metastatic testicular non seminomatous germ cell tumours (abstract 521). Proc Am Soc Clin Oncol 8: 134
Logothetis CJ, Samuels M, Trindade A, Johnson DE (1982) The growing teratoma syndrome. Cancer 50: 1629–1635
Motzer RJ, Bosl GJ, Tauer K, Golbey R (1987) Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin. Cancer Treat Rep 71: 197–198
Motzer RJ, Cooper K, Geller NL, Pfister DG, Lin S, Bajorin D, Scher HI, Herr H, Fair W, Morse M, Sogain P, Whitmore W, Bosl GJ (1990) Carboplatin + etoposide + bleomycin for patients with poor risk germ cell tumors. Cancer 65: 2465–2471
Newell DR, Eeles RA, Gumbrell LA, Boxall FE, Horwich A, Calvert AH (1989) Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. Cancer Chemother Pharmacol 23: 367–372
Nisselbaum JS, Bosl GJ, Golbey RB, Schwartz DC, Schwartz MK (1984) Changes in serum alpha-fetoprotein and chorionic gonadotropin in response to cancer therapy. Ann Clin Lab Sci 14: 179–188
Prestayko AE, Luft F, Einhorn L, Crooke ST (1978) Cisplatin pharmacokinetics in a patient with renal dysfunction. Med Pediatr Oncol 5: 183–188
Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr H, Morse M, Sogani P, Vaughan E, Bander N, Weiselber L, Geller N, Hollander P, Lipperman R, Fair W, Whitmore W (1988). M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461–469
Sulkes A, Collins JM (1987) Reappraisal of some dosage adjustment guidelines. Cancer Treat Rep 71: 229–233
Vogelzang NJ, Lange PH, Goldman A, Vessala RH, Fraley EE, Kennedy BJ (1982) Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 42: 4855–4861
Williams S, Birch R, Einhorm LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316: 1435–1440
Author information
Authors and Affiliations
Additional information
Robert J. Motzer, M. D., is a recipient of an American Cancer Society Career Development Award
Rights and permissions
About this article
Cite this article
Motzer, R.J., Niedzwiecki, D., Isaacs, M. et al. Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother. Pharmacol. 27, 234–238 (1990). https://doi.org/10.1007/BF00685719
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685719